This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-17 (canceled)

Claim 18 (new): A composition comprising a pharmacologically effective amount of a pharmaceutically acceptable amine and a pharmacologically effective amount of a pharmaceutically acceptable nonsteroidal anti-inflammatory drug, wherein said amine and pharmaceutically acceptable nonsteroidal anti-inflammatory drug are provided in a suspension having a liquid medium wherein at least said pharmaceutically acceptable nonsteroidal anti-inflammatory drug is substantially suspended in the liquid medium, said suspension comprised of at least one suspending agent; and a taste masking agent selected from the group consisting of sugar, sweet polyhydric alcohol, cyclamates, aspartame, sucralose saccharin, flavoring agents and mixtures thereof, wherein the composition provides an enhanced absorption rate of the amine into the blood of a human compared with a corresponding composition comprising the amine but not the pharmaceutically acceptable nonsteroidal anti-inflammatory drug.

Claim 19 (new): The composition of claim 18 wherein the at least one suspending agent includes a compound selected from the group consisting of polycarbohydrates, wetting agents, sulfonates and nonionic materials.

Claim 20 (new): The composition of claim 19 wherein the suspending agent includes at least one polycarbohydrate selected from the group consisting of cellulose derivates, starch and starch derivatives, xanthum gum, carageenan and locust bean gum.

Claim 21 (new): The composition of claim 19 wherein the suspending agent includes a wetting agent selected from the group consisting of sodium laurel sulfates and alkyl polyoxyethylene sulfates.

Claim 22 (new): The composition of claim 18 wherein the pharmaceutically acceptable nonsteroidal anti-inflammatory drug is ibuprofen and the pharmaceutically acceptable amine is pseudoephedrine.

Claim 23 (new): The composition of claim 22 wherein the ibuprofen is provided at dosage of about 100 milligrams and the pseudoephedrine is provided at a dosage of about 15 milligrams per 5 mL.

Claim 24 (new): The composition of claim 22 where the pseudoephedrine is provided in a range from about 15 mg to about 60 mg per dosage unit.

Claim 25 (new): The composition of claim 22 where the ibuprofen is provided in a range from about 40 mg to about 800 mg per dosage unit.

Claim 26 (new): The composition of claim 22 wherein the enhanced absorption is indicated by AUC 1 H that is at least about 10% higher than the early drug exposure of the same amine from a single-ingredient liquid.

Claim 27 (new): The composition of claim 22 wherein the enhanced absorption is indicated by AUC 2 H that is at least about 10% higher than the early drug exposure of the same amine from a single-ingredient liquid.

Claim 28 (new): The composition of claim 22 wherein the enhanced absorption is indicated by a CMAX that is at least about 10% greater than the CMAX of the same amine from a single-ingredient liquid.

Claim 29 (new): A suspension having a liquid medium comprising a pharmacologically effective amount of a pharmaceutically acceptable amine and a pharmacologically effective amount of a pharmaceutically acceptable nonsteroidal anti-inflammatory drug which is substantially suspended in the liquid medium, wherein the suspension provides an enhanced absorption rate of the amine into the blood of a human compared with a corresponding suspension comprising the amine but not the pharmaceutically acceptable nonsteroidal anti-inflammatory drug.

Claim 30 (new): The suspension of claim 29 wherein the pharmaceutically acceptable nonsteroidal anti-inflammatory drug is ibuprofen and the pharmaceutically acceptable amine is pseudoephedrine.

Claim 31 (new): The suspension of claim 29 wherein the ibuprofen is provided at dosage of about 100 milligrams and the pseudoephedrine is provided at a dosage of about 15 milligrams per 5 mL.

Claim 32 (new): The suspension of claim 29 where the pseudoephedrine is provided in a range from about 15 mg to about 60 mg per dosage unit.

Claim 33 (new): The suspension of claim 29 where the ibuprofen is provided in a range from about 40 mg to about 800 mg per dosage unit.

Claim 34 (new): The suspension of claim 29 wherein the enhanced absorption is indicated by AUC 1 H that is at least about 10% higher than the early drug exposure of the same amine from a single-ingredient liquid.

Claim 35 (new): The suspension of claim 29 wherein the enhanced absorption is indicated by AUC 2 H that is at least about 10% higher than the early drug exposure of the same amine from a single-ingredient liquid.

Claim 36 (new): The suspension of claim 29 wherein the enhanced absorption is indicated by a CMAX that is at least about 10% greater than the CMAX of the same amine from a single-ingredient liquid.